Coronavirus disease 2019 hospitalization outcomes in persons with and without HIV in Spain.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
entrez:
24
3
2022
pubmed:
25
3
2022
medline:
30
3
2022
Statut:
ppublish
Résumé
To compare coronavirus disease 2019 (COVID-19) hospitalization outcomes between persons with and without HIV. Retrospective observational cohort study in 150 hospitals in Spain. Patients admitted from 1 March to 8 October 2020 with COVID-19 diagnosis confirmed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 positive) PCR test in respiratory tract samples. The primary data source was the COVID-19 Sociedad Española de Medicina Interna's registry (SEMI-COVID-19). Demographics, comorbidities, vital signs, laboratory parameters, and clinical severity as well as treatments received during admission, treatment duration, ICU admission, use of invasive mechanical ventilation, and death were recorded. Factors associated with mortality and the composite of ICU admission, invasive mechanical ventilation, and death, were analyzed. Data from 16 563 admissions were collected, 98 (0.59%) of which were of persons with HIV infection. These patients were younger, the percentage of male patients was higher, and their Charlson comorbidity index was also higher. Rates of mortality and composite outcome of ICU admission, invasive mechanical ventilation or death were lower among patients with HIV infection. In the logistic regression analysis, HIV infection was associated with an adjusted odds ratio of 0.53 [95% confidence interval (CI) 0.29-0.96] for the composite outcome. HIV infection was associated with a lower probability of ICU admission, invasive mechanical ventilation, or death.
Identifiants
pubmed: 35323157
doi: 10.1097/QAD.0000000000003056
pii: 00002030-202204010-00009
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
683-690Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
European Centre for Disease Prevention and Control. COVID-19 situation update worldwide, as of week 3, updated 28 January 2021. Available at: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncovcases [Accessed 3 February]
The novel Coronavirus Pneumonia emergency response epidemiology team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020 . China CDC Weekly 2020; 2:113–122.
Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study . Lancet 2020; 395:1763–1770.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy . JAMA 2020; 323:1574–1581.
Boulle A, Davies MA, Hussey H, Ismail M, Morden E, Vundle Z, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa . Clin Infect Dis 2020; ciaa1198[Epub ahead of print].
Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, et al. Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study . Clin Infect Dis 2020; ciaa1605[Epub ahead of print].
Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform . Lancet HIV 2021; 8:e24–e32.
Sigel K, Swartz T, Golden E, Paranjpe I, Somani S, Richter F, et al. Coronavirus 2019 and people living with human immunodeficiency virus: outcomes for hospitalized patients in New York City . Clin Infect Dis 2020; 71:2933–2938.
Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review . HIV Med 2020; 21:567–577.
Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State . JAMA Netw Open 2021; 4:e2037069.
Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection . Adv Immunol 2013; 119:51–83.
So-Armah KA, Tate JP, Chang CH, Butt AA, Gerschenson M, Gibert CL, et al. Do biomarkers of inflammation, monocyte activation, and altered coagulation explain excess mortality between HIV infected and uninfected people? . J Acquir Immune Defic Syndr 2016; 72:206–213.
Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study . Life Sci 2020; 253:117592.
Del Amo J, Polo R, Moreno S, Diaz A, Martinez E, Arribas JR, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study . Ann Intern Med 2020; 173:536–541.
Ayerdi O, Puerta T, Clavo P, Vera M, Ballesteros J, Fuentes ME, et al. Preventive efficacy of tenofovir/emtricitabine against severe acute respiratory syndrome coronavirus 2 among pre-exposure prophylaxis users . Open Forum Infect Dis 2020; 7:ofaa455.
Casas-Rojo JM, Anton-Santos JM, Millan-Nunez-Cortes J, Lumbreras-Bermejo C, Ramos-Rincon JM, Roy-Vallejo E, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry . Rev Clin Esp 2020; 220:480–494.
Patel VV, Felsen UR, Fisher M, Fazzari MJ, Ginsberg MS, Beil R, et al. Clinical outcomes and inflammatory markers by hiv serostatus and viral suppression in a large cohort of patients hospitalized with COVID-19 . J Acquir Immune Defic Syndr 2021; 86:224–230.
Group RC. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial . Lancet 2020; 396:1345–1352.